For help on how to get the results you want, see our search tips.
2 results
Referral type
Article 20 procedures Remove Article 20 procedures filter
Article 29 paediatrics Remove Article 29 paediatrics filter
Referral status
European Commission final decision Remove European Commission final decision filter
Procedure started Remove Procedure started filter
Categories
Human Remove Human filter
Medicine type
Biosimilar Remove Biosimilar filter
Additional monitoring Remove Additional monitoring filter
Medicine
Referrals Remove Referrals filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020